We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Regeneron/Roche COVID-19 Antibody Cocktail Cuts Hospitalizations and Deaths
Regeneron/Roche COVID-19 Antibody Cocktail Cuts Hospitalizations and Deaths
Regeneron Pharmaceuticals’ and Roche’s antibody cocktail, REGEN-COV (casirivimab/imdevimab), reduced the risk of hospitalization or death by 70 percent in high-risk nonhospitalized COVID-19 patients in a late-stage trial, the companies have said.